(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Ski Resorts Universally: A Colder time of year Wonderland Guide - 2Taylor Swift changes 2 song lyrics on 'Reputation' on the night of her Eras tour documentary premiere
- 3Parents who delay baby's first vaccines also likely to skip measles shots
- 4Which Kind of Pet Makes the Incomparable Buddy?
- 5Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Iran Used $2 Billion in Crypto to Run Its Militant Proxies in 2025
- Ways to track down the Right Criminal Legal counselor
- The most effective method to Consummate the Specialty of Handshaking in Business and Group environments
- 7 Odd Apparatuses to Make Your Party Stick Out!
- The 10 Most Noteworthy Games in History
- Climate leaders are talking about 'overshoot' into warming danger zone. Here's what it means
- A definitive Manual for 2024's Most In vogue Wedding Dresses
- The Green Transformation: 5 Feasible Living Practices
- Motivational Travel Objections for History Buffs
